---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011596"
form_type: "8-K"
ticker: null
cik: "0001100397"
company_name: "Ayala Pharmaceuticals, Inc."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:27:24.377383+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Ayala Pharmaceuticals dismisses Marcum as auditor, engages KFGK for FY 2023

## Summary
- Audit committee discontinued Marcum engagement on April 5, 2023; no disagreements with Marcum.
- Marcum's audit reports for FY ended Oct 2022 and 2021 included a going concern explanatory paragraph.
- KFGK (Kost, Forer, Gabbay & Kasierer, member of EY Global) engaged to audit FY ending Dec 31, 2023.
- Change follows reverse merger where Old Ayala is accounting acquirer; KFGK previously audited Old Ayala's 2022/2021 financials.

## SEC filing metadata
- accession: 0001493152-23-011596
- form_type: 8-K
- cik: 0001100397
- company_name: Ayala Pharmaceuticals, Inc.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 4.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100397/000149315223011596/0001493152-23-011596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100397/000149315223011596/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011596
- JSON: https://secwatch.observer/filing/0001493152-23-011596.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011596.txt

## Key facts
- Auditor Changes
  Ayala Pharmaceuticals, Inc. dismissed Marcum LLP as its auditor.
  - Action: dismissal
  - Auditor: Marcum LLP
  source text: 1, 2022 and 2021 were audited by Marcum LLP (“Marcum”). After the completion of the Merger, the audit committee of the Registrant’s board of directors (the “Audit Committee”), which has the responsibility to engage and dismiss the Registrant’s auditor under Rule 10A-3(b)(2), made the decision to continue the engagement of both KFGK and Marcum, KFGK to serve as the independent registered public accounting firm to audit the consolidated financial statements of Old Ayala (the accounting acquiror in the Merger) for the year ended December 31, 2022 and Marcum to serve as the independent registered public accounting firm to audit the consolidated financial statements of Pre-Merger Advaxis (the accounting acquiree in the Merger) for the year ended October 31, 2022. Dismissal of Independent Registered Public Accounting Firm On April 5, 2023, the Audit Committee determined to discontinue the enga
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223011596/0001493152-23-011596-index.htm
- Auditor Changes
  Ayala Pharmaceuticals, Inc. engaged Kost, Forer, Gabbay & Kasierer as its auditor.
  - Action: engagement
  - Auditor: Kost, Forer, Gabbay & Kasierer
  source text: inancial statements of Old Ayala as of and for the years ended December 31, 2022 and 2021 were audited by Kost, Forer, Gabbay & Kasierer, a Member of EY Global (“KFGK”). The financial statements of Pre-Merger Advaxis as of and for the years ended October 31, 2022 and 2021 were audited by Marcum LLP (“Marcum”). After the completion of the Merger, the audit committee of the Registrant’s board of directors (the “Audit Committee”), which has the responsibility to engage and dismiss the Registrant’s auditor under Rule 10A-3(b)(2), made the decision to continue the engagement of both KFGK and Marcum, KFGK to serve as the independent registered public accounting firm to audit the consolidated financial
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223011596/0001493152-23-011596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.